Astellas Pharma Inc.
Stock Price Chart
2026/03/03 UpdatedPrice Trend
2026/03/03 UpdatedPrice & Trading Details
2026/03/03 UpdatedPRICE
TRADING
Analyst Recommendations 13 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
26.0M | +0.15% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
23.0M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
16.5M | +2.67% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
12.3M | -0.50% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
6.5M | +1.56% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
6.2M | -1.52% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
2.0M | +83.84% | |
|
Paradigm Asset Management Company, LLC
|
5.1K | 0.00% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥76 | +5.6% |
| 2024 | ¥72 | +10.8% |
| 2023 | ¥65 | +18.2% |
| 2022 | ¥55 | +19.6% |
| 2021 | ¥46 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,296,163M | ¥1,518,619M | ¥1,603,672M | ¥1,912,323M |
| Gross Profit | ¥1,043,154M | ¥1,230,266M | ¥1,311,187M | ¥1,563,117M |
| Operating Income | ¥130,963M | ¥131,557M | ¥18,947M | ¥40,248M |
| Pretax Income | ¥161,835M | ¥141,140M | ¥36,974M | ¥48,914M |
| Net Income | ¥124,086M | ¥98,714M | ¥17,045M | ¥50,747M |
| EPS | ¥67.05 | ¥54.09 | ¥9.47 | ¥28.24 |
| Operating Margin | 10.10% | 8.66% | 1.18% | 2.10% |
| Balance Sheet | ||||
| Total Assets | ¥2,332,395M | ¥2,456,518M | ¥3,569,603M | ¥3,339,544M |
| Total Equity | ¥1,460,308M | ¥1,507,954M | ¥1,595,988M | ¥1,513,255M |
| Total Liabilities | ¥872,087M | ¥948,564M | ¥1,973,615M | ¥1,826,289M |
| Cash | ¥315,986M | ¥376,840M | ¥335,687M | ¥188,372M |
| Interest-bearing Debt | - | ¥125,000M | ¥920,016M | ¥831,426M |
| Equity Ratio | 62.61% | 61.39% | 44.71% | 45.31% |
| D/E Ratio | 0.00 | 0.08 | 0.58 | 0.55 |
| Cash Flow | ||||
| Operating CF | ¥257,444M | ¥327,767M | ¥172,475M | ¥194,512M |
| Investing CF | -¥62,413M | -¥84,500M | -¥845,802M | -¥89,419M |
| Financing CF | -¥216,298M | -¥195,623M | ¥614,060M | -¥261,367M |
| Free CF | ¥180,996M | ¥239,226M | ¥89,978M | ¥137,182M |
| Efficiency | ||||
| ROE | 8.50% | 6.55% | 1.07% | 3.35% |
| ROA | 5.32% | 4.02% | 0.48% | 1.52% |
Latest IR Information
-
Sustainability Meeting 2025
Astellas Pharma is promoting company-wide initiatives and setting indicators to improve sustainability. The social impact for FY2024 is reported as Product Impact of USD 27,861 million, Human Capital Impact of USD 528.5 million, and Environmental Impact of -USD 32.7 million.
Read more -
Settlement with Lupin and Zydus in Myrbetriq® Patent Infringement Lawsuit
Astellas Pharma reached a settlement with Lupin and Zydus in the Myrbetriq® patent infringement lawsuit, receiving a total of USD 60 million in settlement payments and USD 150 million in upfront license fees.
Read more -
Antibody-Drug Conjugate PADCEV TM (Enfortumab Vedotin) Shows Favorable Results in Phase III EV-304 Trial for Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Astellas Pharma announced that the combination therapy of PADCEV (Enfortumab Vedotin) and Pembrolizumab improved event-free survival and overall survival in cisplatin-eligible muscle-invasive bladder cancer in the Phase III EV-304 trial.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥2,100
Rating Score: 2.64 (Based on 13 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
